The ptx therapy review is an article about ptx therapy, an anticancer drug that works against a variety of cancers. Ptx is a member of the antineoplastic family of drugs and is used to treat many different types of cancers, including some forms of non-small cell lung cancer (NSCLC).
The main purpose of ptx is to kill cancer cells. It works by interfering with the function of microtubules in the cell. The drug blocks the re-assembly of microtubules after mitosis and stalls the progression of cell division in dividing cells. This leads to the formation of apoptosis in the cell [2].
PTX is able to target cancer cells through several mechanisms including apoptosis, inhibition of chromosome segregation and interference with microtubule dynamics. PTX also acts as a tumor suppressor through the inhibition of cellular proliferation, metastasis and angiogenesis. It has also been shown that PTX affects epigenetic markers in breast cancer cells by modulating the expression of cellular genes.
In addition to its direct action against cancer cells, PTX has been proven to have beneficial effects on the immune system. It has been shown to induce activation of dendric cells, macrophages and cytotoxic T lymphocytes. In addition it has been demonstrated that PTX can modulate the expression of inflammatory cytokines and chemokines in patients with sepsis.
Our explicit aim is to find the optimal dosage of PTX in combination with antibiotics. In order to achieve this we will use the stepwise method in which a group of 3 consecutive patients will receive the same PTX dose. After a short time we will assess the efficacy of that dosage based on clinical and chemical effect, as well as adverse drug reactions. The dosage will be increased/decreased in accordance with predefined up/down dosing adjustments for the next cohort of 3 patients.
